NCT01246349Source recordAI-normalized
Motivational Interviewing as an Intervention to Increase Adolescent Self-Efficacy and Promote Weight Loss
The study, sponsored by The Hospital for Sick Children, evaluated the efficacy of Motivational Interviewing (MI) in promoting weight loss and self-efficacy among adolescents aged 10-18 years with obesity. Given the rising prevalence of childhood obesity, this intervention addresses a significant public health concern. The results could position MI as a viable therapeutic approach in pediatric obesity management, potentially leading to market opportunities in behavioral health interventions. Competitive implications include the need to assess existing behavioral therapies and their effectiveness compared to MI. Diligence should focus on the scalability of MI in clinical settings and potential partnerships with obesity clinics and health organizations.
AI analysis
Indication: Childhood Obesity
Modality: behavioral intervention
Target: Motivational Interviewing (MI) as a behavioral intervention to enhance intrinsic motivation and self-efficacy in overweight adolescents.
Sponsor: The Hospital for Sick Children
Source URL: ClinicalTrials.gov
Source updated: Nov 17, 2017
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: Childhood Obesity
View original source fields
Condition raw: Childhood Obesity
Condition normalized: Childhood Obesity
Modality raw: behavioral intervention
Modality normalized: behavioral intervention
Target raw: Motivational Interviewing (MI) as a behavioral intervention to enhance intrinsic motivation and self-efficacy in overweight adolescents.
Target normalized: Motivational Interviewing (MI) as a behavioral intervention to enhance intrinsic motivation and self-efficacy in overweight adolescents.
NCT00623792Source recordAI-normalized
Preoperative Lifestyle Intervention in Bariatric Surgery
The trial, sponsored by Duquesne University, evaluates a preoperative lifestyle intervention aimed at improving outcomes for bariatric surgery candidates. Given the rising prevalence of obesity and the increasing demand for bariatric procedures, successful outcomes from this intervention could enhance patient compliance and reduce postoperative complications, potentially leading to broader adoption in clinical practice. The competitive landscape includes various lifestyle and behavioral modification programs, but this trial's focus on a structured preoperative intervention may differentiate it. The findings could inform future guidelines and reimbursement strategies, impacting market dynamics in obesity management.
AI analysis
Indication: Severe Obesity
Modality: behavioral intervention
Target: Preoperative lifestyle intervention targeting diet, exercise, and surgical preparation.
Sponsor: Duquesne University
Source URL: ClinicalTrials.gov
Source updated: Mar 17, 2016
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: Severe Obesity
View original source fields
Condition raw: Severe Obesity, Bariatric Surgery
Condition normalized: Severe Obesity, Bariatric Surgery
Modality raw: behavioral intervention
Modality normalized: behavioral intervention
Target raw: Preoperative lifestyle intervention targeting diet, exercise, and surgical preparation.
Target normalized: Preoperative lifestyle intervention targeting diet, exercise, and surgical preparation.
NCT06994338Source recordAI-normalized
Phase II Evaluation of Tirzepatide in Adults With Alcohol Use Disorder and Overweight or Obesity
Tirzepatide, a GLP-1 receptor agonist, is currently being evaluated for its efficacy in reducing alcohol consumption and improving cardiometabolic health in adults with Alcohol Use Disorder (AUD) and obesity. The trial is sponsored by the University of Southern California and is actively recruiting participants. If successful, this indication could expand Tirzepatide's market potential beyond diabetes and obesity, tapping into the significant unmet need for effective treatments for AUD. The competitive landscape includes existing pharmacotherapies for AUD, such as naltrexone and acamprosate, but Tirzepatide's novel mechanism may offer a differentiated profile. Diligence should focus on the trial's design, recruitment pace, and any emerging safety or efficacy signals that could impact market entry timelines and commercial viability.
AI analysis
Indication: Alcohol Use Disorder
Modality: small molecule
Target: GLP-1 receptor agonism, potentially influencing alcohol consumption and cardiometabolic outcomes.
Sponsor: University of Southern California
Source URL: ClinicalTrials.gov
Source updated: Oct 14, 2025
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: Obesity and Overweight
View original source fields
Condition raw: Alcohol Use Disorder, Obesity and Overweight, Alcohol
Condition normalized: Alcohol Use Disorder, Obesity and Overweight, Alcohol
Modality raw: small molecule
Modality normalized: small molecule
Target raw: GLP-1 receptor agonism, potentially influencing alcohol consumption and cardiometabolic outcomes.
Target normalized: GLP-1 receptor agonism, potentially influencing alcohol consumption and cardiometabolic outcomes.
NCT05276544Source recordAI-normalized
The Effect of Telephone and Video Counseling Given to Obese Individuals on Weight Loss and Quality of Life in the COVID-19 Pandemic: an RCT
Individuals with obesity are at higher risk for severe disease, hospitalizations, and death from the SARS-CoV-2 virus. Social distancing guidelines intended to prevent viral spread during the COVID-19 pandemic resulted in major changes to daily routines . Several studies have demonstrated that individuals with overweight/obesity reported worsening mental health, poor eating habits , less physical activity (PA) since the onset of the COVID-19 pandemic. Because of these pandemic rules, the use of phone/video consultancy applications and online classes for body weight control and diet monitoring is increasing. Therefore, in this study it is aimed to determine the effect of diet counseling via phone or video on weight loss and to compare it with the traditional follow-up method in the COVID-19 pandemic.
AI analysis
Indication: Weight Loss
Modality: behavioral intervention
Target: Dietary intervention
Sponsor: Ankara University
Source URL: ClinicalTrials.gov
Source updated: Jul 20, 2022
Ingested: Jun 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: Weight Loss
View original source fields
Condition raw: Weight Loss, Obesity
Condition normalized: Weight Loss, Obesity
Modality raw: behavioral intervention
Modality normalized: behavioral intervention
Target raw: Dietary intervention
Target normalized: Dietary intervention
NCT07466017Source recordAI-normalized
A Randomized, Double-blind, Placebo-controlled, Parallel-group Phase II Study to Evaluate the Efficacy and Safety of CS060380 Tablets in Patients With Metabolic Dysfunction-associated Steatohepatitis (MASH) and Obesity.
Cascade Pharmaceuticals, Inc. is advancing CS060380 in a Phase II trial to evaluate its efficacy and safety in combination with semaglutide for treating MASH and obesity. The market for obesity and related liver diseases is significant, with increasing prevalence globally. The combination therapy approach may provide a competitive edge against existing treatments, particularly as semaglutide has shown promise in weight management. Successful trial outcomes could position Cascade favorably in a growing market, but diligence is required regarding regulatory pathways and potential competition from other obesity and liver disease therapies.
AI analysis
Indication: Metabolic Dysfunction-associated Steatohepatitis (MASH)
Modality: small molecule
Target: CS060380 is a THR-beta agonist targeting metabolic dysfunction-associated steatohepatitis (MASH) and obesity.
Sponsor: Cascade Pharmaceuticals, Inc
Source URL: ClinicalTrials.gov
Source updated: May 20, 2026
Ingested: Jun 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: Obesity
View original source fields
Condition raw: Metabolic Dysfunction-associated Steatohepatitis (MASH), Obesity
Condition normalized: Metabolic Dysfunction-associated Steatohepatitis (MASH), Obesity
Modality raw: small molecule
Modality normalized: small molecule
Target raw: CS060380 is a THR-beta agonist targeting metabolic dysfunction-associated steatohepatitis (MASH) and obesity.
Target normalized: CS060380 is a THR-beta agonist targeting metabolic dysfunction-associated steatohepatitis (MASH) and obesity.
NCT06296511Source recordAI-normalized
The Influence of Acute Moderate-intensity Continuous Exercise on Appetite Regulation
A key area of obesity research has focused on the link between appetite, energy balance and weight control. Within this area, several appetite-related hormones and cellular cytokines have been identified as key signals influencing appetite and food intake. This includes the appetite-suppressing hormone oxyntomodulin (OXM) and a cellular stress-induced cytokine growth differentiation factor 15 (GDF-15). The aims of this study are: (1) to investigate the effect of acute moderate-intensity continuous exercise on oxyntomodulin and GDF-15 concentrations; (2) to investigate whether exercise-induced changes in circulating OXM and GDF-15 concentrations are correlated with subjective appetite perceptions and subsequent energy intake.
AI analysis
Indication: Obesity
Modality: behavioral intervention
Target: Exercise
Sponsor: Loughborough University
Source URL: ClinicalTrials.gov
Source updated: Mar 06, 2024
Ingested: Jun 08, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: Obesity
View original source fields
Condition raw: Obesity, Overweight
Condition normalized: Obesity, Overweight
Modality raw: behavioral intervention
Modality normalized: behavioral intervention
Target raw: Exercise
Target normalized: Exercise
NCT02456636Source recordAI-normalized
Rural Engagement in Primary Care for Optimizing Weight Reduction (RE-POWER)
The purpose of this study is to compare three methods for managing obesity in rural patients, to see which method will result in patients being able to attain their weight loss goal and maintain that weight loss.
AI analysis
Indication: Obesity
Modality: behavioral intervention
Target: Fee-for-Service Model (FFS, In clinic individual visits), Patient Centered Medical Home (PCMH, In clinic group visits), Disease Management (DM, Phone group visits)
Sponsor: University of Kansas Medical Center
Source URL: ClinicalTrials.gov
Source updated: Dec 07, 2020
Ingested: Jun 08, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: Obesity
View original source fields
Condition raw: Obesity
Condition normalized: Obesity
Modality raw: behavioral intervention
Modality normalized: behavioral intervention
Target raw: Fee-for-Service Model (FFS, In clinic individual visits), Patient Centered Medical Home (PCMH, In clinic group visits), Disease Management (DM, Phone group visits)
Target normalized: Fee-for-Service Model (FFS, In clinic individual visits), Patient Centered Medical Home (PCMH, In clinic group visits), Disease Management (DM, Phone group visits)
NCT07055607Source recordAI-normalized
A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice
A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice is a registry-stage clinical asset sponsored by Novo Nordisk A/S in Obesity. SEO and diligence focus: Semaglutide, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
AI analysis
Indication: Obesity
Modality: small molecule
Target: Semaglutide
Sponsor: Novo Nordisk A/S
Source URL: ClinicalTrials.gov
Source updated: May 14, 2026
Ingested: Jun 08, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: Obesity
View original source fields
Condition raw: Obesity
Condition normalized: Obesity
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Semaglutide
Target normalized: Semaglutide
NCT07395960Source recordAI-normalized
The Efficacy and Safety of Metformin Intervention in Elderly Overweight or Obesity With Mild Cognitive Impairment by a Single-center, Randomized, Placebo-controlled Interventional Study (Include Elderly Patients With Obesity or Overweight)
The prevalence of cognitive impairment in elderly obese patients is high, and the burden on families and society is heavy. Early intervention for mild cognitive impairment (MCI) is of great value. Central nervous system insulin resistance plays a role in the pathogenesis of cognitive impairment, and functional magnetic resonance imaging(fMRI) can evaluate cognitive impairment by observing central insulin resistance. Some large database studies of Type 2 Diabetes show that metformin is related to reducing the risk of dementia, but some studies have different conclusions, and there is few related study in elderly obese patients. The investigators speculate that metformin may improve cognitive dysfunction by improving central insulin resistance in elderly obese patients. A prospective, randomized controlled single center clinical cohort study will be conducted on 54 elderly obese patients with MCI. One group will receive metformin and lifestyle intervention, while the control group will receive simple lifestyle intervention. All subjects will be followed up for 26 weeks. Medical history collection, physical examination, and laboratory tests will be conducted before and after intervention, and the Montreal Cognitive Assessment Scale will be used for evaluation. Nasal insulin inhalation combined with fMRI will be used to evaluate central insulin resistance status as an objective basis for cognitive function evaluation. The main purpose of the study is to provide more accurate clinical research evidence for the prevention and treatment of MCI in elderly obese patients, in order to reduce the risk of developing dementia and alleviate the burden on families and society.
AI analysis
Indication: Mild Cognitive Impairment
Modality: small molecule
Target: Metfomin
Sponsor: Fudan University
Source URL: ClinicalTrials.gov
Source updated: Feb 09, 2026
Ingested: Jun 07, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by conditions: Overweight or Obesity
View original source fields
Condition raw: Mild Cognitive Impairment, Overweight or Obesity, Elderly
Condition normalized: Mild Cognitive Impairment, Overweight or Obesity, Elderly
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Metfomin
Target normalized: Metfomin